Table 1.
General characteristics of the study patients
| Variable | Entire cohort | Training group | Validation group | P | |
|---|---|---|---|---|---|
| n = 75 | n = 45 (60.0%) | n = 30 (40.0%) | |||
| Age: median [range], years | 52 [20-81] | 53 [22-78] | 51 [20-81] | 0.240 | |
| Sex | Female | 40 (53.3) | 25 (55.6) | 15 (50.0) | 0.646 |
| Male | 35 (46.7) | 20 (44.4) | 15 (50.0) | ||
| Smoking | Yes | 21 (28.0) | 12 (26.7) | 9 (30.0) | 0.797 |
| No | 54 (72.0) | 33 (73.3) | 21 (70.0) | ||
| Performance | ECOG 0 − 1 | 72 (96.0) | 43 (95.6) | 29 (96.7) | 1.000 |
| ECOG 2 | 3 (4.0) | 2 (4.4) | 1 (3.3) | ||
| Treatment | Surgery | 45 (60.0) | 30 (66.7) | 15 (50.0) | 0.160 |
| Non-surgery | 30 (40.0) | 15 (33.3) | 15 (50.0) | ||
| WHO histology | High-risk | 60 (80.0) | 38 (84.4) | 22 (73.3) | 0.255 |
| Low-risk | 15 (20.0) | 7 (15.6) | 8 (26.7) | ||
| T-stage | T1 − T2 | 31 (41.3) | 16 (35.6) | 15 (50.0) | 0.239 |
| T3 − T4 | 44 (58.7) | 29 (64.4) | 15 (50.0) | ||
| N-stage | N0 − N2b | 71 (94.7) | 42 (93.3) | 29 (96.7) | 0.646 |
| N2c − N3 | 4 (5.3) | 3 (6.7) | 1 (3.7) | ||
| AJCC stage | I − II | 23 (30.7) | 12 (26.7) | 11 (36.7) | 0.445 |
| III − IV | 52 (69.3) | 33 (73.3) | 19 (63.3) | ||
| Dead events | 27 (36.0) | 19 (42.2) | 8 (26.7) | 0.222 | |
| Relapse events | 31 (41.3) | 18 (40.0) | 13 (43.3) | 0.814 | |